Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

    ... 24 weeks of subcutaneous darbepoetin alfa 500 μg or placebo every 3 weeks (Q3W), followed by 48 weeks of open-label darbepoetin ... 5-24 was significantly lower with darbepoetin alfa versus placebo (36.1% [35/97] versus 59.2% [29/49], P=0.008] and erythroid response ...

    Research Article last updated 07/11/2017 - 10:16am.

  2. Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

    ... treatment arms (in the randomized, double-blinded, placebo -controlled Phase 2 portion). ...

    Clinical Trial last updated 06/19/2017 - 2:44pm.

  3. CASCADE (SGN33A-005)

    ... decitabine extends overall survival longer than placebo combined with either azacitidine or decitabine. ...

    Clinical Trial last updated 06/19/2017 - 2:43pm.

  4. Eltrombopag Added to IST Yields Encouraging Results

    ... patients are randomly assigned to receive a sugar pill/ placebo instead of eltrombopag – whereas in our study all patients ...

    Interview last updated 05/24/2017 - 7:44am.

  5. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

    ... (2:1) to receive eltrombopag (50 mg to 300 mg) or placebo for at least 24 weeks and until disease progression and were masked ... the eltrombopag group versus one (3%) of 31 patients in the placebo group (odds ratio 27·1 [95% CI 3·5-211·9], p=0·0017). During the ...

    Research Article last updated 02/21/2017 - 9:49am.

  6. Advances in antiviral drug cuts infection post SCT

    ... research centers in 20 countries, compared letermovir to placebo in preventing an active CMV infection following transplant with ... weeks of treatment, 61 percent of the patients receiving a placebo had developed a CMV infection serious enough to require treatment or ...

    Article last updated 02/23/2017 - 7:26am.

  7. MEDALIST Trial

    ... This is a Phase 3, double-blind, randomized, placebo -controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in subjects with anemia due to International Prognostic ...

    Clinical Trial last updated 02/22/2017 - 11:42am.

  8. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes

    ... azacitidine . METHODS: A phase 2 randomized, placebo -controlled clinical trial of azacitidine and pracinostat ... there were 51 in the pracinostat group and 51 in the placebo group. The median age was 69 years. The CR rate by cycle 6 of therapy ...

    Research Article last updated 02/03/2017 - 11:12am.

  9. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... PURPOSE: This international phase III, randomized, placebo -controlled, double-blind study assessed the efficacy and safety of ... assigned (2:1) to treatment with lenalidomide (n = 160) or placebo (n = 79) once per day (on 28-day cycles). The primary end point was the ...

    Research Article last updated 07/18/2016 - 10:30am.

  10. Interviews with the Experts: Side Effects of PNH Treatment

    ... receiving eculizumab and 9 (21%) patients receiving placebo (inactive ingredient). Among 193 patients with PNH treated with ...

    Interview last updated 08/31/2016 - 8:37am.